3-(3-phenylpropyl)hexahydropyrimidin-2-one | 1219980-35-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(3-phenylpropyl)hexahydropyrimidin-2-one
• 英文别名: 1-(3-Phenylpropyl)-1,3-diazinan-2-one
• CAS: 1219980-35-4
• 化学式: C₁₃H₁₈N₂O
• 分子量: 218.299
• InChiKey: UIVIPIYIITYWBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3-phenylpropyl)hexahydropyrimidin-2-one 在 劳森试剂 作用下， 以 甲苯 为溶剂， 以68%的产率得到3-(3-phenylpropyl)hexahydropyrimidine-2-thione
  参考文献：
  名称：

  Inhibitory effect of novel tetrahydropyrimidine-2(1H)-thiones on melanogenesis

  摘要：

  The series of imidazoldine-2-thiones 2 and tetrahydropyrimidine-2-thiones 3 were discovered as inhibitor of alpha-MSH-induced melanin production in melanoma B16 cells. The primary bioassay showed that 1-(4-ethylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3e (> 100% inhibition at 10 mu M, IC50 = 1.2 mu M) and 1-(4-tert-butylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3f (> 100% inhibition at 10 mu M, IC50 = 0.76 mu M) exhibited potent inhibitory effect against alpha-MSH-induced melanin production. Compounds 3 inhibit the biosynthesis of tyrosinase without affecting its catalytic activity in melanogenesis. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.12.044
• 作为产物：
  描述：

  tert-butyl 3-(3-phenylpropylamino)propylcarbamate 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以55%的产率得到3-(3-phenylpropyl)hexahydropyrimidin-2-one
  参考文献：
  名称：

  Inhibitory effect of novel tetrahydropyrimidine-2(1H)-thiones on melanogenesis

  摘要：

  The series of imidazoldine-2-thiones 2 and tetrahydropyrimidine-2-thiones 3 were discovered as inhibitor of alpha-MSH-induced melanin production in melanoma B16 cells. The primary bioassay showed that 1-(4-ethylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3e (> 100% inhibition at 10 mu M, IC50 = 1.2 mu M) and 1-(4-tert-butylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3f (> 100% inhibition at 10 mu M, IC50 = 0.76 mu M) exhibited potent inhibitory effect against alpha-MSH-induced melanin production. Compounds 3 inhibit the biosynthesis of tyrosinase without affecting its catalytic activity in melanogenesis. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.12.044

文献信息

• 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
  申请人：The Industry & Academic Cooperation in Chungnam National University (IAC) 충남대학교산학협력단(220040084104) BRN ▼314-82-09264

  公开号：KR20150111825A

  公开（公告）日：2015-10-06

  본 발명은 강심 활성을 지니는 화합물 및 이를 함유하는 약학적 조성물을 개시하며, 본 발명에 따른 화합물을 포함하는 조성물은 심부전의 예방 및 치료에 유용하다.

  本发明揭示了具有强心活性的化合物以及含有该化合物的药学组合物，根据本发明的含有该化合物的组合物对预防和治疗心力衰竭很有用。
• [EN] COMPOUND HAVING CARDIOTONIC ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEART FAILURE, CONTAINING SAME<br/>[FR] COMPOSÉ DOTÉ D'UNE ACTION CARDIOTONIQUE ET COMPOSITION PHARMACEUTIQUE PERMETTANT DE PRÉVENIR OU DE TRAITER L'INSUFFISANCE CARDIAQUE ET CONTENANT LEDIT COMPOSÉ<br/>[KO] 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
  申请人：IAC IN NAT UNIV CHUNGNAM

  公开号：WO2015142001A2

  公开（公告）日：2015-09-24

  본 발명은 강심 활성을 지니는 화합물 및 이를 함유하는 약학적 조성물을 개시하며, 본 발명에 따른 화합물을 포함하는 조성물은 심부전의 예방 및 치료에 유용하다.
• Inhibitory effect of novel tetrahydropyrimidine-2(1H)-thiones on melanogenesis
  作者：P. Thanigaimalai、Ki-Cheul Lee、Seong-Cheol Bang、Jee-Hyun Lee、Cheong-Yong Yun、Eunmiri Roh、Bang-Yeon Hwang、Youngsoo Kim、Sang-Hun Jung

  DOI：10.1016/j.bmc.2009.12.044

  日期：2010.2

  The series of imidazoldine-2-thiones 2 and tetrahydropyrimidine-2-thiones 3 were discovered as inhibitor of alpha-MSH-induced melanin production in melanoma B16 cells. The primary bioassay showed that 1-(4-ethylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3e (> 100% inhibition at 10 mu M, IC50 = 1.2 mu M) and 1-(4-tert-butylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3f (> 100% inhibition at 10 mu M, IC50 = 0.76 mu M) exhibited potent inhibitory effect against alpha-MSH-induced melanin production. Compounds 3 inhibit the biosynthesis of tyrosinase without affecting its catalytic activity in melanogenesis. (C) 2010 Elsevier Ltd. All rights reserved.